LeukoDx has developed a revolutionary cartridge-based multi-wavelength fluorescent event detection and analysis platform for rapid and efficient measurement and characterization of fluorescently labeled cells and beads to enable multiplexed immunoassays. LeukoDx’s Accellix platform is a no prep, push-button cell enumeration and characterization platform that can provide multiple fluorescent marker information in a single cartridge with close to real time access, 24/7 when and where critical decisions must be made. LeukoDx has offices in San Jose, CA and Jerusalem, Israel. www.LeukoDx.com
Miltenyi Biotec’s mission is to improve scientific understanding and medical progress. We provide products and services that advance biomedical research and cellular therapy. Honoring this mission drives our commitment to support the translation of basic research into therapy in the areas of immunology, cancer, neuroscience and stem cell biology. We innovate products that address sample preparation, separation of cells and their analysis, and that advance the concept of cellular therapy.
Oxford Genetics is a synthetic biology company specialising in DNA design, protein expression optimisation and cell line development technologies and services. These systems are built upon a modular DNA expression system (SnapFastTM) that allows us to rapidly create complex DNA expression systems expressing any genes of interest with maximal protein expresion levels.
Promab Biotechnologies provides a completely comprehensive CAR-T pre-clinical package, allowing for accelerated proof-of-concept, and IP positioning, beginning with the generation of a mouse, rabbit, or human (library) monoclonal antibody, or with the synthesis and cloning of existing antibody sequence into a CAR expression construct. Promab is positioned to explore collaboration with partners in order to rapidly expand clinical targets. Read more here.
Retrogenix provides a fast, accurate and effective solution for primary receptor identification and specificity screening of antibodies, protein ligands, CAR T cells, viruses and small molecules. Physiologically-relevant targets are identified by screening for interactions against the most comprehensive set of plasma membrane proteins available in the context of human cells. This specific sensitive technology is widely used by major global pharmaceutical companies to advance drug discovery and development, predominantly in biologics research.
TCR2 Therapeutics is pioneering a novel class of T cell therapies that utilize the full signalling power of T cell receptors (TCR). Its proprietary TRuC™ platform has demonstrated superior activity against solid and haematological targets in preclinical models compared to CAR-T. The company believes its TRuC™-T cells will serve as a backbone for solid tumor therapies. TCR2 was founded in 2015 with a $44.5M Series A financing led by MPM Capital and F2 Ventures.
Vineti combines industry-leading software expertise with deep first-hand, knowledge of commercializing personalized cell therapies to digitize the supply chain, manufacturing and compliance systems for the delivery of transformational medicines. Vineti’s user-centric design creates a platform that is easier for physicians, nurses, and manufacturing operations to use, resulting in a superior user experience and reduced risk. The Vineti platform provides actionable insights to continually optimize the process, accelerating time to revenue and decreasing costs.
Blood Centers of America (BCA) is a national network of over 50 independent blood centers with just over 600 fixed collection and testing sites positioned throughout the country. BCA and its members provide a variety of human blood products, cells and tissues to the therapeutic, diagnostic and cell therapy industries. Whether you are sourcing research or clinical grade materials; blood or tissue derived products, or custom collections and/or collection services, BCA has a solution for you. Our network of centers can assist from the discovery phase to commercialization… Read More www.bca.coop
Cognate is a dynamic, results-driven, organization focused on providing the broadest range of commercialization services to regenerative medicine and advance cell therapy companies, organizations and institutions. Cognate provides specialized custom services to companies across all points of clinical and commercial development ranging from early preclinical studies, to mid phase trials and product scale-up though later stage clinical trials and commercial manufacturing.
As a not-for-profit research and development company, Draper focuses on the design, development and deployment of advanced technological solutions for the world’s most challenging and important problems. Draper’s Biomedical Solutions encompass organ-on-chip systems, cell therapy bioprocessing devices, rapid diagnostics, and neurotechnology.